APA (7th ed.) Citation

Singh, D., Balaguer, V., Astbury, C., Wählby-Hamrén, U., Jimenez, E., Seoane, B., . . . Psallidas, I. (2020). Navafenterol (AZD8871) in patients with COPD: A randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator. Respiratory Research, 21(1), 1. https://doi.org/10.1186/s12931-020-01347-7

Chicago Style (17th ed.) Citation

Singh, Dave, et al. "Navafenterol (AZD8871) in Patients with COPD: A Randomized, Double-blind, Phase I Study Evaluating Safety and Pharmacodynamics of Single Doses of This Novel, Inhaled, Long-acting, Dual-pharmacology Bronchodilator." Respiratory Research 21, no. 1 (2020): 1. https://doi.org/10.1186/s12931-020-01347-7.

MLA (9th ed.) Citation

Singh, Dave, et al. "Navafenterol (AZD8871) in Patients with COPD: A Randomized, Double-blind, Phase I Study Evaluating Safety and Pharmacodynamics of Single Doses of This Novel, Inhaled, Long-acting, Dual-pharmacology Bronchodilator." Respiratory Research, vol. 21, no. 1, 2020, p. 1, https://doi.org/10.1186/s12931-020-01347-7.